drugset / Trial / NCT04040322
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.
Timeline
- Start
- 2019-10-14
- Primary completion
- 2021-06-09
- Completion
- 2021-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Iloprost | Other / unclassified | 0.5 ng/ml | Intravenous |
| Comparator | Iloprost | Other / unclassified | 2 ng/ml | Intravenous |